Retromer deficiency in Tauopathy models enhances the truncation and toxicity of Tau.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
27 08 2022
Historique:
received: 07 05 2018
accepted: 10 08 2022
entrez: 27 8 2022
pubmed: 28 8 2022
medline: 31 8 2022
Statut: epublish

Résumé

Alteration of the levels, localization or post-translational processing of the microtubule associated protein Tau is associated with many neurodegenerative disorders. Here we develop adult-onset models for human Tau (hTau) toxicity in Drosophila that enable age-dependent quantitative measurement of central nervous system synapse loss and axonal degeneration, in addition to effects upon lifespan, to facilitate evaluation of factors that may contribute to Tau-dependent neurodegeneration. Using these models, we interrogate the interaction of hTau with the retromer complex, an evolutionarily conserved cargo-sorting protein assembly, whose reduced activity has been associated with both Parkinson's and late onset Alzheimer's disease. We reveal that reduction of retromer activity induces a potent enhancement of hTau toxicity upon synapse loss, axon retraction and lifespan through a specific increase in the production of a C-terminal truncated isoform of hTau. Our data establish a molecular and subcellular mechanism necessary and sufficient for the depletion of retromer activity to exacerbate Tau-dependent neurodegeneration.

Identifiants

pubmed: 36030267
doi: 10.1038/s41467-022-32683-5
pii: 10.1038/s41467-022-32683-5
pmc: PMC9420134
doi:

Substances chimiques

tau Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5049

Subventions

Organisme : NIH HHS
ID : P40 OD018537
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS095922
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Weingarten, M. D., Lockwood, A. H., Hwo, S. Y. & Kirschner, M. W. A protein factor essential for microtubule assembly. Proc. Natl Acad. Sci. USA 72, 1858–1862 (1975).
pubmed: 1057175 pmcid: 432646 doi: 10.1073/pnas.72.5.1858
Migheli, A., Butler, M., Brown, K. & Shelanski, M. L. Light and electron microscope localization of the microtubule-associated tau protein in rat brain. J. Neurosci. 8, 1846–1851 (1988).
pubmed: 3133453 pmcid: 6569338 doi: 10.1523/JNEUROSCI.08-06-01846.1988
Papasozomenos, S. C. & Binder, L. I. Phosphorylation determines two distinct species of Tau in the central nervous system. Cell Motil. Cytoskeleton 8, 210–226 (1987).
pubmed: 2446784 doi: 10.1002/cm.970080303
Black, M. M., Slaughter, T., Moshiach, S., Obrocka, M. & Fischer, I. Tau is enriched on dynamic microtubules in the distal region of growing axons. J. Neurosci. 16, 3601–3619 (1996).
pubmed: 8642405 pmcid: 6578833 doi: 10.1523/JNEUROSCI.16-11-03601.1996
Didonna, A. Tau at the interface between neurodegeneration and neuroinflammation. Genes Immun. 21, 288–300 (2020).
pubmed: 33011744 doi: 10.1038/s41435-020-00113-5
Kovacs, G. G. Tauopathies. Handb. Clin. Neurol. 145, 355–368 (2018).
doi: 10.1016/B978-0-12-802395-2.00025-0
de Calignon, A. et al. Caspase activation precedes and leads to tangles. Nature 464, 1201–1204 (2010).
pubmed: 20357768 pmcid: 3091360 doi: 10.1038/nature08890
Ozcelik, S. et al. Co-expression of truncated and full-length tau induces severe neurotoxicity. Mol. Psychiatry 21, 1790–1798 (2016).
pubmed: 26830137 pmcid: 5116481 doi: 10.1038/mp.2015.228
Vaz-Silva, J. et al. Endolysosomal degradation of Tau and its role in glucocorticoid-driven hippocampal malfunction. EMBO J. 37, e99084 (2018).
pubmed: 30166454 pmcid: 6187216 doi: 10.15252/embj.201899084
Lee, M. J., Lee, J. H. & Rubinsztein, D. C. Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog. Neurobiol. 105, 49–59 (2013).
pubmed: 23528736 doi: 10.1016/j.pneurobio.2013.03.001
Zhang, Y., Chen, X., Zhao, Y., Ponnusamy, M. & Liu, Y. The role of ubiquitin proteasomal system and autophagy-lysosome pathway in Alzheimer’s disease. Rev. Neurosci. 28, 861–868 (2017).
pubmed: 28704199 doi: 10.1515/revneuro-2017-0013
Khanna, M. R., Kovalevich, J., Lee, V. M. Y., Trojanowski, J. Q. & Brunden, K. R. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimer’s Dement. 12, 1051–1065 (2016).
doi: 10.1016/j.jalz.2016.06.006
Bonifacino, J. S. & Hurley, J. H. Retromer. Curr. Opin. Cell Biol. 20, 427–436 (2008).
pubmed: 18472259 pmcid: 2833274 doi: 10.1016/j.ceb.2008.03.009
Liu, J. J. Retromer-mediated protein sorting and vesicular trafficking. J. Genet. Genomics 43, 165–177 (2016).
pubmed: 27157806 doi: 10.1016/j.jgg.2016.02.006
Wang, S. & Bellen, H. J. The retromer complex in development and disease. Development 142, 2392–2396 (2015).
pubmed: 26199408 pmcid: 4510866 doi: 10.1242/dev.123737
Mukadam, A. S. & Seaman, M. N. J. Retromer-mediated endosomal protein sorting: The role of unstructured domains. FEBS Lett. 589, 2620–2626 (2015).
pubmed: 26072290 doi: 10.1016/j.febslet.2015.05.052
McMillan, K. J., Korswagen, H. C. & Cullen, P. J. The emerging role of retromer in neuroprotection. Curr. Opin. Cell Biol. 47, 72–82 (2017).
pubmed: 28399507 pmcid: 5677836 doi: 10.1016/j.ceb.2017.02.004
Small, S. A. & Petsko, G. A. Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nat. Rev. Neurosci. 16, 126–132 (2015).
pubmed: 25669742 doi: 10.1038/nrn3896
Vilariño-Güell, C. et al. VPS35 mutations in parkinson disease. Am. J. Hum. Genet. 89, 162–167 (2011).
pubmed: 21763482 pmcid: 3135796 doi: 10.1016/j.ajhg.2011.06.001
Rahman, A. A. & Morrison, B. E. Contributions of VPS35 mutations to Parkinson’s disease. Neuroscience 401, 1–10 (2019).
pubmed: 30660673 doi: 10.1016/j.neuroscience.2019.01.006
Cui, Y., Yang, Z. & Teasdale, R. D. The functional roles of retromer in Parkinson’s disease. FEBS Lett. 592, 1096–1112 (2018).
pubmed: 29210454 doi: 10.1002/1873-3468.12931
Williams, E. T., Chen, X. & Moore, D. J. VPS35, the retromer complex and Parkinson’s disease. J. Parkinson’s Dis. 7, 219–233 (2017).
doi: 10.3233/JPD-161020
Rovelet-Lecrux, A. et al. De novo deleterious genetic variations target a biological network centered on Aβ peptide in early-onset Alzheimer disease. Mol. Psychiatry 20, 1046–1056 (2015).
pubmed: 26194182 doi: 10.1038/mp.2015.100
Simoes, S. et al. Tau and other proteins found in Alzheimer’ s disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans. Sci. Transl. Med. 12, eaba6334 (2020).
Small, S. A. et al. Model-guided microarray implicates the retromer complex in Alzheimer’s disease. Ann. Neurol. 58, 909–919 (2005).
pubmed: 16315276 doi: 10.1002/ana.20667
Temkin, P. et al. The retromer supports AMPA receptor trafficking during LTP. Neuron 94, 74–82.e5 (2017).
pubmed: 28384478 doi: 10.1016/j.neuron.2017.03.020
Wen, L. et al. VPS35 haploinsufficiency increases Alzheimer’s disease neuropathology. J. Cell Biol. 195, 765–779 (2011).
pubmed: 22105352 pmcid: 3257571 doi: 10.1083/jcb.201105109
Sullivan, C. P. et al. Retromer disruption promotes amyloidogenic APP processing. Neurobiol. Dis. 43, 338–345 (2011).
pubmed: 21515373 pmcid: 3114192 doi: 10.1016/j.nbd.2011.04.002
Young, J. E. et al. Stabilizing the retromer complex in a human stem cell model of Alzheimer’s disease reduces TAU phosphorylation independently of amyloid precursor protein. Stem Cell Rep. 10, 1046–1058 (2018).
doi: 10.1016/j.stemcr.2018.01.031
Barthélemy, N. R. et al. A soluble phosphorylated Tau signature links Tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat. Med. 26, 398–407 (2020).
pubmed: 32161412 pmcid: 7309367 doi: 10.1038/s41591-020-0781-z
Barthélemy, N. R. et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification. Alzheimer’s Res. Ther. 12, 26 (2020).
Santa-Maria, I. et al. Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of Tau. J. Clin. Invest. 125, 681–686 (2015).
pubmed: 25574843 pmcid: 4319412 doi: 10.1172/JCI78421
Shulman, J. M. & Feany, M. B. Genetic modifiers of tauopathy in Drosophila. Genetics 165, 1233–1242 (2003).
pubmed: 14668378 pmcid: 1462852 doi: 10.1093/genetics/165.3.1233
McGuire, S. E., Mao, Z. & Davis, R. L. Spatiotemporal gene expression targeting with the TARGET and gene-switch systems in Drosophila. Sci. Signal. 2004, pl6–pl6 (2004).
Burnouf, S. et al. Deletion of endogenous Tau proteins is not detrimental in Drosophila. Sci. Rep. 6, 23102 (2016).
pubmed: 26976084 pmcid: 4792132 doi: 10.1038/srep23102
Papanikolopoulou, K. et al. Drosophila Tau negatively regulates translation and olfactory Long-Term Memory, but facilitates footshock habituation and cytoskeletal homeostasis. J. Neurosci. 39, 8315–8329 (2019).
pubmed: 31488613 pmcid: 6794924 doi: 10.1523/JNEUROSCI.0391-19.2019
Kneynsberg, A., Combs, B., Christensen, K., Morfini, G. & Kanaan, N. M. Axonal degeneration in tauopathies: disease relevance and underlying mechanisms. Front. Neurosci. 11, 1–14 (2017).
doi: 10.3389/fnins.2017.00572
Hassan, B. A. et al. Atonal regulates neurite arborization but does not act as a proneural gene in the Drosophila brain. Neuron 25, 549–561 (2000).
pubmed: 10774724 doi: 10.1016/S0896-6273(00)81059-4
Langen, M. et al. Mutual inhibition among postmitotic neurons regulates robustness of brain wiring in Drosophila. Elife 1–21, https://doi.org/10.7554/eLife.00337 (2013).
Miura, E. et al. VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson’s disease. Neurobiol. Dis. 71, 1–13 (2014).
pubmed: 25107340 doi: 10.1016/j.nbd.2014.07.014
Ye, H. et al. Retromer subunit, VPS29, regulates synaptic transmission and is required for endolysosomal function in the aging brain. Elife 788711, https://doi.org/10.1101/788711 (2020).
Tsika, E. et al. Parkinson’s disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Hum. Mol. Genet. 23, 4621–4638 (2014).
pubmed: 24740878 pmcid: 4119414 doi: 10.1093/hmg/ddu178
Wang, Y. & Mandelkow, E. Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 5–21 (2016).
pubmed: 26631930 doi: 10.1038/nrn.2015.1
Iqbal, K., Liu, F. & Gong, C. X. Tau and neurodegenerative disease: the story so far. Nat. Rev. Neurol. 12, 15–27 (2016).
pubmed: 26635213 doi: 10.1038/nrneurol.2015.225
Wang, J. Z., Xia, Y. Y., Grundke-Iqbal, I. & Iqbal, K. Abnormal hyperphosphorylation of Tau: Sites, regulation, and molecular mechanism of neurofibrillary degeneration. Adv. Alzheimer’s Dis. 3, 123–139 (2012).
doi: 10.3233/JAD-2012-129031
Gamblin, T. C. et al. Caspase cleavage of Tau: linking amyloid and neurofibrillary tangles in Alzheimer’s disease. Proc. Natl Acad. Sci. USA 100, 10032–10037 (2003).
pubmed: 12888622 pmcid: 187753 doi: 10.1073/pnas.1630428100
Khurana, V. et al. Lysosomal dysfunction promotes cleavage and neurotoxicity of Tau in vivo. PLoS Genet. 6, 1–11 (2010).
doi: 10.1371/journal.pgen.1001026
Novak, P., Cehlar, O., Skrabana, R. & Novak, M. Tau conformation as a target for disease-modifying therapy: the role of truncation. J. Alzheimer’s Dis. 64, S535–S546 (2018).
doi: 10.3233/JAD-179942
Nicholls, S. B. et al. Characterization of TauC3 antibody and demonstration of its potential to block Tau propagation. PLoS ONE 12, 1–11 (2017).
doi: 10.1371/journal.pone.0177914
Matthews-Roberson, T. A., Quintanilla, R. A., Ding, H. & Johnson, G. V. W. Immortalized cortical neurons expressing caspase-cleaved Tau are sensitized to endoplasmic reticulum stress induced cell death. Brain Res. 1234, 206–212 (2008).
pubmed: 18718455 pmcid: 2572685 doi: 10.1016/j.brainres.2008.07.111
Dorstyn, L., Colussi, P. A., Quinn, L. M., Richardson, H. & Kumar, S. DRONC, an ecdysone-inducible Drosophila caspase. Proc. Natl Acad. Sci. USA 96, 4307–4312 (1999).
pubmed: 10200258 pmcid: 16328 doi: 10.1073/pnas.96.8.4307
Dorstyn, L. et al. The role of cytochrome c in caspase activation in Drosophila melanogaster cells. J. Cell Biol. 156, 1089–1098 (2002).
pubmed: 11901173 pmcid: 2173478 doi: 10.1083/jcb.200111107
Xu, D., Li, Y., Arcaro, M., Lackey, M. & Bergmann, A. The CARD-carrying caspase Dronc is essential for most, but not all, developmental cell death in Drosophila. Development 132, 2125–2134 (2005).
pubmed: 15800001 doi: 10.1242/dev.01790
Bao, Q. & Shi, Y. Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ. 14, 56–65 (2006).
pubmed: 16977332 doi: 10.1038/sj.cdd.4402028
Huh, J. R. et al. Multiple apoptotic caspase cascades are required in nonapoptotic roles for Drosophila spermatid individualization. PLoS Biol. 2, e15 (2003).
pubmed: 14737191 pmcid: 300883 doi: 10.1371/journal.pbio.0020015
Huh, J. R., Guo, M. & Hay, B. A. Compensatory proliferation induced by cell death in the Drosophila wing disc requires activity of the apical cell death caspase dronc in a nonapoptotic role. Curr. Biol. 14, 1262–1266 (2004).
pubmed: 15268856 doi: 10.1016/j.cub.2004.06.015
Jo, J. et al. Drosophila caspase activity is required independently of apoptosis to produce active TNF/Eiger during nociceptive sensitization. Cell Death Dis. 8, e2786–e2786 (2017).
pubmed: 28492538 pmcid: 5520682 doi: 10.1038/cddis.2016.474
Arthurton, L., Nahotko, D. A., Alonso, J., Wendler, F. & Baena‐Lopez, L. A. Non‐apoptotic caspase activation preserves Drosophila intestinal progenitor cells in quiescence. EMBO Rep. 21, e48892 (2020).
Banerjee, S. et al. dHb9 expressing larval motor neurons persist through metamorphosis to innervate adult-specific muscle targets and function in Drosophila eclosion. Dev. Neurobiol. 76, 1387–1416 (2016).
pubmed: 27168166 pmcid: 5106342 doi: 10.1002/dneu.22400
Banerjee, S. et al. Miniature neurotransmission is required to maintain Drosophila synaptic structures during ageing. Nat. Commun. 12, 1–12 (2021).
doi: 10.1038/s41467-021-24490-1
Manders, E. M. M., Verbeek, F. J. & Aten, J. A. Measurement of co‐localization of objects in dual‐colour confocal images. J. Microsc. 169, 375–382 (1993).
pubmed: 33930978 doi: 10.1111/j.1365-2818.1993.tb03313.x
Meduri, G. et al. Caspase-cleaved Tau-D421 is colocalized with the immunophilin FKBP52 in the autophagy-endolysosomal system of Alzheimer’s disease neurons. Neurobiol. Aging 46, 124–137 (2016).
pubmed: 27479154 doi: 10.1016/j.neurobiolaging.2016.06.017
Bucci, C., Thomsen, P., Nicoziani, P., McCarthy, J. & van Deurs, B. Rab7: a key to lysosome biogenesis. Mol. Biol. Cell 11, 467–480 (2000).
pubmed: 10679007 pmcid: 14786 doi: 10.1091/mbc.11.2.467
Rojas, R. et al. Regulation of retromer recruitment to endosomes by sequential action of Rab5 and Rab7. J. Cell Biol. 183, 513–526 (2008).
pubmed: 18981234 pmcid: 2575791 doi: 10.1083/jcb.200804048
Harmansa, S., Alborelli, I., Bieli, D., Caussinus, E. & Affolter, M. A nanobody-based toolset to investigate the role of protein localization and dispersal in Drosophila. eLife 6, e22549 (2017).
Dunst, S. et al. Endogenously tagged rab proteins: a resource to study membrane trafficking in Drosophila. Dev. Cell 33, 351–365 (2015).
pubmed: 25942626 pmcid: 4431667 doi: 10.1016/j.devcel.2015.03.022
Kovacech, B. & Novak, M. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimers disease. Curr. Alzheimer Res. 7, 708–716 (2010).
pubmed: 20678071 doi: 10.2174/156720510793611556
Zhou, Y. et al. Relevance of phosphorylation and truncation of Tau to the etiopathogenesis of Alzheimer’s disease. Front. Aging Neurosci. 10, 27 (2018).
pubmed: 29472853 pmcid: 5810298 doi: 10.3389/fnagi.2018.00027
Liu, P. et al. A soluble truncated Tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals. Sci. Rep. 10, 1–18 (2020).
Zhang, Z. et al. Cleavage of Tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nat. Med. 20, 1254–1262 (2014).
pubmed: 25326800 pmcid: 4224595 doi: 10.1038/nm.3700
Chung, C.-W. et al. Proapoptotic effects of Tau cleavage product generated by caspase-3. Neurobiol. Dis. 8, 162–172 (2001).
pubmed: 11162250 doi: 10.1006/nbdi.2000.0335
Rissman, R. A. et al. Caspase-cleavage of Tau is an early event in Alzheimer disease tangle pathology. J. Clin. Invest. 114, 121–130 (2004).
pubmed: 15232619 pmcid: 437967 doi: 10.1172/JCI200420640
Jarero-Basulto, J. J. et al. Proteolytic cleavage of polymeric Tau protein by caspase-3: implications for Alzheimer disease. J. Neuropathol. Exp. Neurol. 72, 1145–1161 (2013).
pubmed: 24226268 doi: 10.1097/NEN.0000000000000013
Berry, R. W. et al. Inhibition of Tau polymerization by its carboxy-terminal caspase cleavage fragment. Biochemistry 42, 8325–8331 (2003).
pubmed: 12846581 doi: 10.1021/bi027348m
Quinn, J. P., Corbett, N. J., Kellett, K. A. B. & Hooper, N. M. Tau Proteolysis in the pathogenesis of tauopathies: neurotoxic fragments and novel biomarkers. J. Alzheimer’s Dis. 63, 13–33 (2018).
doi: 10.3233/JAD-170959
Zhao, Y. et al. Appoptosin-mediated caspase cleavage of Tau contributes to progressive supranuclear palsy pathogenesis. Neuron 87, 963–975 (2015).
pubmed: 26335643 pmcid: 4575284 doi: 10.1016/j.neuron.2015.08.020
Evans, L. D. et al. Extracellular monomeric and aggregated Tau efficiently enter human neurons through overlapping but distinct pathways. Cell Rep. 22, 3612–3624 (2018).
pubmed: 29590627 pmcid: 5896171 doi: 10.1016/j.celrep.2018.03.021
Caballero, B. et al. Interplay of pathogenic forms of human Tau with different autophagic pathways. Aging Cell 17, e12692 (2018).
doi: 10.1111/acel.12692
Carosi, J. M. et al. Retromer regulates the lysosomal clearance of MAPT / Tau. Autophagy 00, 1–21 (2020).
Vagnozzi, A. N. et al. VPS35 regulates Tau phosphorylation and neuropathology in tauopathy. Mol. Psychiatry https://doi.org/10.1038/s41380-019-0453-x (2019).
Hu, Y.-B., Dammer, E. B., Ren, R.-J. & Wang, G. The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration. Transl. Neurodegener. 4, 1–10 (2015).
doi: 10.1186/s40035-015-0041-1
Vagnozzi, A. N. & Praticò, D. Endosomal sorting and trafficking, the retromer complex and neurodegeneration. Mol. Psychiatry https://doi.org/10.1038/s41380-018-0221-3 (2018).
Walker, L. C. Aβ Plaques. Free Neuropathol. 1, 31 (2020).
Cataldo, A. M. et al. Aβ localization in abnormal endosomes: association with earliest Aβ elevations in AD and Down syndrome. Neurobiol. Aging 25, 1263–1272 (2004).
pubmed: 15465622 doi: 10.1016/j.neurobiolaging.2004.02.027
Small, S. A., Simoes-Spassov, S., Mayeux, R. & Petsko, G. A. Endosomal traffic jams represent a pathogenic hub and therapeutic target in Alzheimer’s disease. Trends Neurosci. 40, 592–602 (2017).
pubmed: 28962801 pmcid: 5654621 doi: 10.1016/j.tins.2017.08.003
Sorrentino, Z. A. & Giasson, B. I. The emerging role of α-synuclein truncation in aggregation and disease. J. Biol. Chem. 295, 10224–10244 (2020).
pubmed: 32424039 pmcid: 7383394 doi: 10.1074/jbc.REV120.011743
MacLeod, D. A. et al. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson’s disease risk. Neuron 77, 425–439 (2013).
pubmed: 23395371 pmcid: 3646583 doi: 10.1016/j.neuron.2012.11.033
Tang, F.-L. et al. VPS35 in dopamine neurons is required for endosome-to-golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for synuclein degradation and prevention of pathogenesis of Parkinson’s disease. J. Neurosci. 35, 10613–10628 (2015).
pubmed: 26203154 pmcid: 4510296 doi: 10.1523/JNEUROSCI.0042-15.2015
Greeve, I. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J. Neurosci. 24, 3899–3906 (2004).
pubmed: 15102905 pmcid: 6729409 doi: 10.1523/JNEUROSCI.0283-04.2004
Chen, X. et al. Parkinson’s disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration. Proc. Natl Acad. Sci. USA. 116, 5765–5774 (2019).
pubmed: 30842285 pmcid: 6431187 doi: 10.1073/pnas.1814909116
McGurk, L., Berson, A. & Bonini, N. M. Drosophila as an in vivo model for human neurodegenerative disease. Genetics 201, 377–402 (2015).
pubmed: 26447127 pmcid: 4596656 doi: 10.1534/genetics.115.179457
Bolus, H., Crocker, K., Boekhoff-Falk, G. & Chtarbanova, S. Modeling neurodegenerative disorders in Drosophila melanogaster. Int. J. Mol. Sci. 21, 3055 (2020).
Wang, J. W., Beck, E. S. & McCabe, B. D. A modular toolset for recombination transgenesis and neurogenetic analysis of Drosophila. PLoS ONE 7, e42102 (2012).
pubmed: 22848718 pmcid: 3405054 doi: 10.1371/journal.pone.0042102
Ni, J. Q. et al. A genome-scale shRNA resource for transgenic RNAi in Drosophila. Nat. Methods 8, 405–407 (2011).
pubmed: 21460824 pmcid: 3489273 doi: 10.1038/nmeth.1592
Wang, S. et al. The retromer complex is required for rhodopsin recycling and its loss leads to photoreceptor degeneration. PLoS Biol. 12, e1001847 (2014).
Bischof, J., Sheils, E. M., Björklund, M. & Basler, K. Generation of a transgenic ORFeome library in Drosophila. Nat. Protoc. 9, 1607–1620 (2014).
pubmed: 24922270 pmcid: 4150248 doi: 10.1038/nprot.2014.105
Zhang, J. et al. Thirty-one flavors of Drosophila Rab proteins. Genetics 176, 1307–1322 (2007).
pubmed: 17409086 pmcid: 1894592 doi: 10.1534/genetics.106.066761
Cherry, S. et al. Charcot-Marie-Tooth 2B mutations in rab7 cause dosage-dependent neurodegeneration due to partial loss of function. Elife 2013, 1–22 (2013).
Ellis, M. C., O’Neill, E. M. & Rubin, G. M. Expression of Drosophila glass protein and evidence for negative regulation of its activity in non-neuronal cells by another DNA-binding protein. Development 119, 855–865 (1993).
pubmed: 8187644 doi: 10.1242/dev.119.3.855
Robinow, S. & White, K. The locus elav of Drosophila melanogaster is expressed in neurons at all developmental stages. Dev. Biol. 126, 294–303 (1988).
pubmed: 3127258 doi: 10.1016/0012-1606(88)90139-X
Shearin, H. K., MacDonald, I. S., Spector, L. P. & Steven Stowers, R. Hexameric GFP and mCherry reporters for the Drosophila GAL4, Q, and LexA transcription systems. Genetics 196, 951–960 (2014).
pubmed: 24451596 pmcid: 3982691 doi: 10.1534/genetics.113.161141
Jaerve, A., Schiwy, N., Schmitz, C. & Mueller, H. W. Differential effect of aging on axon sprouting and regenerative growth in spinal cord injury. Exp. Neurol. 231, 284–294 (2011).
pubmed: 21806987 doi: 10.1016/j.expneurol.2011.07.002
Asadzadeh, J. & McCabe, B. D. Tau and retromer dataset, Zenodo, https://doi.org/10.5281/zenodo.6926423 .

Auteurs

Jamshid Asadzadeh (J)

Brain Mind Institute, EPFL - Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland.

Evelyne Ruchti (E)

Brain Mind Institute, EPFL - Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland.

Wei Jiao (W)

Brain Mind Institute, EPFL - Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland.

Greta Limoni (G)

Brain Mind Institute, EPFL - Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland.

Catherine MacLachlan (C)

BioEM Facility, EPFL - Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland.

Scott A Small (SA)

Department of Neurology, Columbia University, New York, USA.
Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, USA.

Graham Knott (G)

Brain Mind Institute, EPFL - Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland.
BioEM Facility, EPFL - Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland.

Ismael Santa-Maria (I)

Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, USA.
Department of Pathology & Cell Biology, Columbia University, New York, USA.
Facultad Ciencias Experimentales, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain.

Brian D McCabe (BD)

Brain Mind Institute, EPFL - Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland. brian.mccabe@epfl.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH